Dutasteride and RU-58841 Interaction: Synergistic | Peptide Database

Corrects age-related glucose tolerance disturbances in primate studies. Reduces incidence and magnitude of metabolic syndrome. Helps control blood sugar through pancreatic function support. Impacts differentiation of pancreatic cells during aging. Improves endocrine function of the pancreas. Addresses age-related imbalance of pancreatic function. Directly interacts with DNA to regulate pancreatic gene expression.

Join others researching Turinabol — share findings, ask questions, and learn from real experiences Turinabol (4-chlorodehydromethyltestosterone) is a synthetic oral anabolic-androgenic steroid developed in the 1960s by Jenapharm, an East German pharmaceutical company. It was created by modifying the structure of methandrostenolone (Dianabol) with a 4-chloro substitution derived from clostebol, producing a compound with a significantly altered pharmacological profile. Turinabol became notorious as the cornerstone of East Germany's state-sponsored doping program (Staatsplan 14.25), which systematically administered the drug to thousands of Olympic athletes from the late 1960s through the 1980s, often without their knowledge. The 4-chloro modification prevents aromatization to estrogen, meaning turinabol does not cause water retention, gynecomastia, or other estrogen-related side effects. This made it particularly attractive for athletes in weight-class sports and those requiring speed, strength, and endurance without visible changes in body mass. Unlike many oral anabolic steroids, turinabol produces slow, steady, lean gains rather than rapid increases in size and strength. It has never been approved for medical use by the FDA or any current Western regulatory body, and it was withdrawn from the market following German reunification and the exposure of the East German doping program. Today it remains one of the most commonly detected substances in anti-doping testing due to the discovery of long-term metabolites detectable for many months after last use. Turinabol exerts its anabolic effects through binding to the intracellular androgen receptor (AR), promoting nitrogen retention, protein synthesis, and positive nitrogen balance in skeletal muscle. The 4-chloro substitution on the A-ring is the defining structural feature, serving two key pharmacological purposes: it completely prevents aromatization by the aromatase enzyme (blocking conversion to estrogenic metabolites), and it reduces the compound's androgenic potency relative to its anabolic activity. This results in a favorable anabolic-to-androgenic ratio, estimated at approximately 54:6 compared to methyltestosterone. Like other 17-alpha-alkylated steroids, turinabol resists first-pass hepatic metabolism, allowing oral bioavailability at the cost of increased hepatic stress. Turinabol enhances protein synthesis through AR-mediated gene transcription and increases red blood cell production, contributing to improved oxygen delivery and muscular endurance. It also promotes creatine phosphate synthesis within muscle cells, supporting ATP regeneration during high-intensity activity. The compound does not significantly interact with 5-alpha reductase, and its androgenic metabolites have low potency, contributing to its relatively mild androgenic side effect profile. It suppresses the hypothalamic-pituitary-gonadal (HPG) axis through negative feedback, reducing endogenous testosterone production in a dose-dependent manner.